fbpx

Nous travaillons au Canada avec les patients en dermatologie pour faire la promotion de la santé cutanée et pour améliorer leur qualité de vie. Nous espérons que l’information contenue sur notre site vous sera utile. N’hésitez pas à nous contacter.

l'Alliance canadienne des patients en dermatologie

Bienvenue à

Image is not available
Image is not available

COVID-19

Image is not available

Pendant cette période d'incertitude, nous partagerons des nouvelles et des informations relatives aux risques et aux impacts de COVID-19. Veillez à rester à jour et à prendre soin de vous.

Rapport sur le HS

Image is not available

Nous avons lancé une mise à jour de notre rapport 2017, Marqué pour la vie. Par le biais de ce rapport, l’ACPD a identifié 11 recommandations à l’intention des fournisseurs de soins de santé et des décideurs qui permettront une meilleure sensibilisation à l’HS, amélioreront les soins, la gestion de la maladie ainsi que la vie des patients atteints d’HS.

Image is not available

Aidez-nous à surveiller la pénurie de médicaments au Canada et à intervenir

Nous sommes très fiers de publier la toute première charte spécifiquement destinée aux patients vivant avec des affections, des maladies et des traumatismes qui affectent la peau.

Image is not available
Charte des patients
previous arrownext arrow
Slider

 

CANADIAN SKIN PATIENT ALLIANCE LAUDS NATIONAL INITIAL RECOMMENDATION FOR NEW MELANOMA DRUGS - URGES QUICK FINAL APPROVAL

Ottawa, Ontario, March 30, 2011 - Today the national drug-review agency, the pan-Canadian Oncology Drug Review (pCODR), announced it is recommending that provinces and territories should consider paying for the skin cancer drugs Yervoy (Ipilimumab) and Zelboraf (Vemurafenib) for the treatment of skin cancer patients whose melanoma has spread from the skin to other organs of the body. 

“Today’s ‘Initial Recommendation’ announcement from pCODR is good news for melanoma patients in Canada,” said Christine Jackson, Executive Director of the Canadian Skin Patient Alliance (CSPA). “We are pleased that pCODR is moving quickly to evaluate these drugs and we hope that the remaining final recommendation will come just as quickly”.

Until now, there has been no approved treatment for advanced melanoma in Canada that had a positive impact on survival for metastatic patients. Yervoy and Zelboraf are first new advanced melanoma treatments to be developed in over a decade. An estimated 5,500 Canadians will be diagnosed with melanoma this year and 950 will die from it. Melanoma is responsible for 75 percent of the deaths associated with skin cancer. Melanoma is clearly visible on the skin, and 90 percent of melanomas are caused by exposure to UV light, including tanning beds.

Unlike traditional chemotherapy which puts toxins into the body to kill cancer, Yervoy works by stimulating the body’s immune system to find and kill cancer cells. Zelboraf works by slowing down or stopping the growth of cancer causing cells with the BRAF gene which drives the development of cancer in about 50% of malignant melanomas. A test can establish which patients possess the gene and are suitable for treatment. Both drugs are for patients who cannot use other systemic treatments or whose cancer has not responded to other systemic treatments.

The CSPA is a national umbrella organization which includes the affiliated skin cancer organizations Alberta Melanoma Society, Save Your Skin Foundation, and the Canadian Skin Cancer Foundation. “Most patients with advanced melanoma now live less than a year,” said Tanny Nadon, Secretary Treasurer of the Melanoma Society of Alberta. “Today’s news is the hope the melanoma community has been waiting on for years,” said David Barnard,  Executive Director of the Save Your Skin Foundation, whose mom has been battling this disease since 2003. Leona Yez, Executive Director of the Canadian Skin Cancer Foundation, added "We are hopeful that the provinces and territories will now put the emphasis on treatments for melanoma and make these two medications available to patients as soon as possible.” 

On January 25th, the CSPA  launched Skin Deep: A Report Card on Access to Dermatological Care and Treatment in Canada. In it, the CSPA called on governments to step up to the plate by immediately providing access to life-saving treatments once they are recommended by pCODR.

Founded in 2007, The Canadian Skin Patient Alliance (CSPA) is a by patients-for-patients, resource and community for all skin patients living with a skin conditions and disorders.  As a national umbrella organization for Canadian not-for-profit patient groups and organizations that deal with skin conditions and diseases, the CSPA is an important hub of skin-health-related information in Canada. As an advocate for awareness, education, research and access to appropriate care, the CSPA represents the voice of the millions of skin patients and their families.

 

For additional information please visit www.canadianskin.ca.

Information:

Ms. Helen Crawford, Media Liaison
Canadian Skin Patient Alliance
Phone: 1-877-505-2772
Cell: 613-299-0878       

 

ASM    CdnSkinCancer Foundation   Save yourskin

Sélectionnez une maladie de la peau:

affiliates

Affiliés actuels

Un certain nombre d'organisations travaillent ensemble avec nous pour améliorer la vie des patients de la peau et de leurs familles au Canada.

Encore...

Canadian Skin Summer 2019 Fre May21 Page 1

Le magazine

Les trois numéros publiés chaque année vous fournissent de l'information qui peut vous fournissent de l'information qui peut vous être utile pour votre problème de peau ou celui d'un de vos proches

Abonnez-vous Notre dernier numéro

Nos commanditaires

L'ACPD tient à remercier nos commanditaires pour 2016. Nous comptons sur ces contributions importantes pour nous aider à répondre aux besoins des patients en dermatologie au Canada.

Slider

donateimage f

Envisagez de soutenir le travail de l'ACPS avec un don

capplogo

Nous sommes fiers de collaborer avec l'Association canadienne des patients atteints de psoriasis

Pour en savoir plus sur l'ACPP et le travail qu'ils font pour les patients canadiens atteints de psoriasis et leurs familles.

Contactez-nous